AZN News Alert Astrazeneca Plc (AZN) 70.44 12/25/2014 17:58:

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 6:58 PM

Astrazeneca Plc (AZN) 70.44 $AZN

Update: Myriad Genetics Won FDA Approval For BRACAnalysis CDx
Andy Batts - at Seeking Alpha - Thu Dec 25, 10:53AM CST

MYGN: 36.50 (+0.28), AZN: 70.44 (+0.26)

Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 1:10PM CST
Myriad Genetics' (MYGN) BracAnalysis CDx has become the first and only FDA-approved test to be permitted for use with AstraZeneca's latest FDA-cleared ovarian cancer drug ??? LynParza.
CYTK: 5.87 (+0.35), MYGN: 36.50 (+0.28), AZN: 70.44 (+0.26), AFFX: 9.80 (+0.05)

The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST

BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)

AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:45PM CST
The FDA has cleared AstraZeneca's (AZN) Lynparza as a monotherapy for the maintenance treatment of adults suffering from advanced ovarian cancer.
AGN: 210.12 (+0.95), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86)

Advaxis continues cancer immunotherapy-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:58AM CST

ADXS: 7.57 (+0.50), AZN: 70.44 (+0.26)

3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)

Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie
PR Newswire - Mon Dec 22, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AstraZeneca (NYSE: AZN), Advaxis (NASDAQ: ADXS), Radius Health (NASDAQ: RDUS), Cubist (NASDAQ: CBST), and AbbVie (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
RDUS: 37.17 (+0.11), ADXS: 7.57 (+0.50), CBST: 100.29 (-0.09), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)

Buying These 3 Stocks Is Like Making a Bet in a Burning House
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 7:54AM CST
Source: Flickr user Mark Esau Bargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over...
OREX: 5.98 (+0.01), AZN: 70.44 (+0.26), VVUS: 2.99 (-0.02), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)

Wall Street Breakfast: China Offers Support For Russia's Currency Crisis
Wall Street Breakfast - Seeking Alpha - Mon Dec 22, 5:29AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Long Top Idea...
AMX: 21.98 (-0.01), FRPT: 15.30 (+1.07), OCN: 14.88 (-0.14), PFE: 31.42 (-0.03), BNFT: 32.78 (+0.75), SNE: 21.32 (+0.46), CZR: 15.44 (+0.20), XL: 34.26 (-0.11), CACQ: 9.96 (+0.12), T: 33.96 (-0.07), JNJ: 104.59 (+0.31), APP: 1.06 (+0.01), ESRX: 85.48 (-0.40), SPY: 207.77 (+0.02), QQQ: 104.30 (+0.09), GILD: 91.29 (+1.84), AZN: 70.44 (+0.26), GM: 33.43 (-0.13), MDW: 0.63 (+0.03), ABBV: 66.21 (+1.86)

The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)

Update: In A Surprise Twist, AstraZeneca Wins Accelerated FDA Approval For Lynparza
Trevor Lowenthal - at Seeking Alpha - Sun Dec 21, 3:32PM CST

AZN: 70.44 (+0.26), PFE: 31.42 (-0.03)

Why Is George Soros Buying This Beaten Down Biotech Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Dec 21, 10:04AM CST
Source: Wikimedia Commons/ Niccolò Caranti The controversial billionaire and hedge fund guru George Soros is undoubtedly one of the best investors on the planet today. At age 83, he is estimated to be the seventh-richest American, with a net...
PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), SRPT: 13.88 (+0.47), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50)

Drug Giants Face $65 Billion in Lost Sales as Insurers Attack Patents
Bruce Japsen, The Motley Fool - Motley Fool - Sun Dec 21, 8:01AM CST
By 2019, pharmaceutical companies face a major loss of $65 billion in sales due to patent expirations largely from brand name central nervous system drugs that are opening up to competition from cheaper generic copies. A new report from...
ESRX: 85.48 (-0.40), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42)

New Pfizer bid unlikely says AstraZeneca CEO
Seeking Alpha - at Seeking Alpha - Sun Dec 21, 6:09AM CST

AZN: 70.44 (+0.26), PFE: 31.42 (-0.03)

A New Study on Diabetes Reveals Potentially Frightening News
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 20, 10:41AM CST
Based on the latest statistics from the CDC, 29.1 million people in the U.S. now have diabetes, of which more than one in four is unaware they have the chronic disease. This is up from 26 million in the CDC's last update. Further, the number of...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), MNKD: 5.68 (+0.18)

AstraZeneca
at Investor's Business Daily - Fri Dec 19, 5:25PM CST
AstraZeneca (AZN) said that the FDA has approved Lynparza, the 1st in a new class of drugs for persistent ovarian cancer associated with certain genetic defects. The company said Thu. that the EU had also approved Lynparza. The FDA also approved a...
MYGN: 36.50 (+0.28), AZN: 70.44 (+0.26)

AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:48PM CST
AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian cancer.
AGN: 210.12 (+0.95), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)

AstraZeneca cancer drug, companion test approved
By LINDA A. JOHNSON - AP - Fri Dec 19, 1:39PM CST
TRENTON, N.J. (AP) — U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC.
MYGN: 36.50 (+0.28), AZN: 70.44 (+0.26)

FDA clears Myriad's companion diagnostic test for Lynparza
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:33AM CST

MYGN: 36.50 (+0.28), AZN: 70.44 (+0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cognizant Boosts Claude AI with 25,000 Pro Workforce

Moving AI from Theory to Practice You know, AI isn't about just keeping up with the hype; it's about shoving those algorithms right where they can do the most good—right at the core of business operations. And that’s precisely what Cognizant's cooking up with their fresh-off-the-press Claude Frontier Capability Group. They’ve thrown more than 25,000 pros into the...

Hexnode XDR Expands Threat Detection, MacOS Support

Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

Gen Z, Millennials Lean on AI Amid Fiscal Crunch

AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...

International Tower Hill's Q3 Results: Gold Updates

An Eye on International Tower Hill's Latest Moves You've got International Tower Hill Mines (TSX: ITH, NYSE American: THM) laying their cards on the table for the third quarter. This ain't just any routine check-in—it's a glimpse at their Livengood Gold Project, standing tall on the promise of gold beyond the horizon. A cool $106 million in cash? Not too shabby, folks....

A Gentle Stake: Colts Neck's Rural Fight Ahead

By Ryan Hughes Updated Nov 10, 2026 Category News Views 101

Michael Fazio's Gambit in Colts Neck If you're not fired up about land deals, you should be now. Michael Fazio, the owner of Synergy Stables in Colts Neck, New Jersey, is laying his cards on the table with a proposition for preserving the integrity of the township's rural landscape. Rather than cashing in on monstrous offers for high-density housing, Fazio's plan involves...

From Vätternrundan to Göta Canal: Circularity in Action

Sustainability in Action: Vätternrundan Leads the Way Ever thought your banana peel could contribute to cultural heritage? That’s the twist here. Vätternrundan 2026 hit the mark by turning food waste into a natural asset along the Göta Canal. It's a glimpse of the future where waste isn't a by-product but a resource. Transforming Waste into Growth In a world where...

1-800Accountant Secures Global Win in Tax Services

Another Feather in the Cap for 1-800Accountant You don’t get to be at the top of your game without turning a few heads. And 1-800Accountant has done just that, snagging the Fall 2026 Clutch Global Award for their expertise in the accounting universe. The Importance of Listening In this day and age, businesses large and small are realizing that the voice of the client is...

Enghouse Acquires MIND CTI: Strategic Telecom Play

Enghouse's Strategic Move into Telecom You want a real shake-up in the telecom space? Here it is. Enghouse Systems Limited (TSX: ENGH) is stepping up its game by acquiring MIND C.T.I. Ltd. (NASDAQ: MNDO). This cash-only transaction is tailored to broaden Enghouse’s suite of offerings in telecom and enterprise unified communications (UC). The price? A neat US$1.30 per...

Freedom Motors USA Appoints Joost de Vries as CEO

Shifts in the Auto World Forget the fact that the family car comes with a couple of new cupholders—over at Freedom Motors USA, they're shaking things up with a CEO change. Nothing says "we mean business" quite like bringing in Joost de Vries to lead the charge into a new era. With this move, Freedom Motors is clearly aiming for bold growth in the sphere of accessible...